[1] Provenzano M, Coppolino G, Faga T, et al. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer.[J]. Reviews in cardiovascular medicine, 2019,20(4).
[2] Lo C, Toyama T, Wang Y, et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease[J]. Cochrane Database Syst Rev, 2018,9:D11798.
[3] De Nicola L, Di Lullo L, Paoletti E, et al. Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice[J]. J Nephrol, 2018,31(5):653-664.
[4] Watanabe R. Hyperkalemia in chronic kidney disease[J]. Rev Assoc Med Bras (1992), 2020,66Suppl 1(Suppl 1):s31-s36.
[5] Kogika M M, de Morais H A. A Quick Reference on Hypokalemia[J]. Vet Clin North Am Small Anim Pract, 2017,47(2):229-234.
[6] Gilligan S, Raphael K L. Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes[J]. Adv Chronic Kidney Dis, 2017,24(5):315-318.
[7] Desai A S, Liu J, Pfeffer M A, et al. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial[J]. J Card Fail, 2018,24(5):313-320.
[8] Yamada S, Inaba M. Potassium Metabolism and Management in Patients with CKD[J]. Nutrients, 2021,13(6).
[9] Ballew S H, Matsushita K. Cardiovascular Risk Prediction in CKD[J]. Semin Nephrol, 2018,38(3):208-216.
[10] Lerner B, Desrochers S, Tangri N. Risk Prediction Models in CKD[J]. Semin Nephrol, 2017,37(2):144-150.
[11] Mei C L, Chen X N, Hao C M, et al. [Development of a hyperkalemia risk assessment model for patients with chronic kidney disease][J]. Zhonghua Yi Xue Za Zhi, 2020,100(44):3498-3503.
[12] Bianchi S, Aucella F, De Nicola L, et al. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology[J]. J Nephrol, 2019,32(4):499-516.
[13] Rushe H, McGee H M. Assessing adherence to dietary recommendations for hemodialysis patients: the Renal Adherence Attitudes Questionnaire (RAAQ) and the Renal Adherence Behaviour Questionnaire (RABQ)[J]. J Psychosom Res, 1998,45(2):149-157.
[14] 陈婕, 娄小平, 申红霞, 等. 回授法饮食管理对腹膜透析患者饮食依从性及营养状况的影响[J]. 中华护理杂志, 2019,54(04):495-500.
[15] Betts K A, Woolley J M, Mu F, et al. The prevalence of hyperkalemia in the United States[J]. Curr Med Res Opin, 2018,34(6):971-978.
[16] Brookes E M, Snider J, Hart G K, et al. Serum potassium abnormalities in chronic kidney disease: prevalence, patient characteristics and clinical outcomes[J]. Intern Med J, 2021,51(11):1906-1918.
[17] Kashihara N, Kohsaka S, Kanda E, et al. Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan[J]. Kidney Int Rep, 2019,4(9):1248-1260.
[18] Korgaonkar S, Tilea A, Gillespie B W, et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study[J]. Clin J Am Soc Nephrol, 2010,5(5):762-769.
[19] He J, Mills K T, Appel L J, et al. Urinary Sodium and Potassium Excretion and CKD Progression[J]. J Am Soc Nephrol, 2016,27(4):1202-1212.
[20] Hassan K. Association of low potassium diet and folic acid deficiency in patients with CKD[J]. Ther Clin Risk Manag, 2015,11:821-827.
[21] Vavruk A M, Martins C, Nascimento M M, et al. [Association between hypokalemia, malnutrition and mortality in peritoneal dialysis patients][J]. J Bras Nefrol, 2012,34(4):349-354.
[22] Clegg D J, Headley S A, Germain M J. Impact of Dietary Potassium Restrictions in CKD on Clinical Outcomes: Benefits of a Plant-Based Diet[J]. Kidney Med, 2020,2(4):476-487.
[23] Ramos C I, Gonzalez-Ortiz A, Espinosa-Cuevas A, et al. Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?[J]. Nephrol Dial Transplant, 2021,36(11):2049-2057.
[24] Hu E A, Coresh J, Anderson C, et al. Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study[J]. Am J Kidney Dis, 2021,77(2):235-244.
[25] Collins A J, Pitt B, Reaven N, et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes[J]. Am J Nephrol, 2017,46(3):213-221.
[26] Markaki A, Kyriazis P, Dermitzaki E K, et al. The Association Between Handgrip Strength and Predialysis Serum Sodium Level in Patients With Chronic Kidney Disease Stage 5D[J]. Front Med (Lausanne), 2020,7:610659.
[27] Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic complications[J]. J Am Soc Nephrol, 2009,20(1):164-171.
[28] Ruilope L M. Angiotensin receptor blockers: RAAS blockade and renoprotection[J]. Curr Med Res Opin, 2008,24(5):1285-1293.
[29] Erraez S, Lopez-Mesa M, Gomez-Fernandez P. [Mineralcorticoid receptor blockers in chronic kidney disease][J]. Nefrologia (Engl Ed), 2021,41(3):258-275.
[30] Saito Y, Yamamoto H, Nakajima H, et al. Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors[J]. PLoS One, 2017,12(9):e184402.